misonidazole has been researched along with Cancer of Pelvis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doss, L; Johnson, R; Meoz, RT; Spanos, WJ; Wasserman, TH | 1 |
| el-Desouky, G; Shafik, A | 1 |
| Kong, J; Meoz, R; Sala, J; Spanos, WJ; Stetz, J; Wasserman, T | 1 |
3 other study(ies) available for misonidazole and Cancer of Pelvis
| Article | Year |
|---|---|
Misonidazole combined with large-fraction pelvic irradiation in the treatment of patients with advanced pelvic malignancies. Preliminary report of an ongoing RTOG phase I-II study.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Middle Aged; Misonidazole; Nitroimidazoles; Palliative Care; Pelvic Neoplasms; Radiotherapy; Radiotherapy, High-Energy | 1983 |
Anal submucosal injection: a new route for drug administration in pelvic malignancies. III. Misonidazole distribution in serum, uterus and vagina: an experimental study.
Topics: Administration, Oral; Administration, Rectal; Animals; Drug Administration Routes; Female; Injections; Misonidazole; Pelvic Neoplasms; Rats; Tissue Distribution; Uterus; Vagina | 1990 |
Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: final report of RTOG phase I/II study.
Topics: Combined Modality Therapy; Female; Humans; Male; Misonidazole; Palliative Care; Pelvic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1987 |